Please assess the completion status of the following clinical trial:

Trial Title: Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult 18-80 year old~* Kidney transplant recipients (de novo or re-transplant, from living or deceased donor)~* BMI over 30~* Recipients with pre formed human leukocyte antigens (HLA) antibodies~* Recipients with donor specific antibodies~* Recipients who have undergone blood type incompatible transplantation (ABO incompatible)~* Recipients who have had prior kidney transplants.~Exclusion Criteria:~* Multi-Visceral transplant (simultaneous kidney pancreas, liver kidney, heart kidney)~* Contraindication to renal biopsy~* Refusing biopsy~* Kidney transplant recipient that is a monozygotic twin to the donor~* When more than two genomes may be present in the recipient plasma (more than recipient + donor): pregnancy, multiple-organ transplants from different donors (kidney after heart, kidney after liver transplant etc.), recipients of allogeneic blood or bone marrow transplant who have received cells with a genome different from the recipient (e.g. non-monozygotic twin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AlloSure Assay prediction of Anti-body Mediated Rejection (Type: None): Determine whether AlloSure predicts the incidence of active, chronic Anti-body Mediated Rejection and cellular rejection in high risk patients

Based on this trial design, predict the completion outcome and termination type (if applicable).